samalizumab

mAbexperimental

Samalizumab is a humanized monoclonal antibody designed for oncology indications. Samalizumab is a recombinant humanized monoclonal antibody that targets the immunoregulatory protein CD200. Results from a Phase I study indicated the drug has potential for use in treating cancers including chronic lymphocytic leukemia. — Wikipedia

Clinical trial activity

3 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Jun 1, 2008 (NCT00648739)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • alxn6000
  • alxn-6000
  • samalizumab
  • samalizumab
  • samalizumab

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02987504Phase 1Nov 1, 2016Alexion, IQVIA
NCT03013998Phase 1/Phase 2 (Phase 2)Nov 1, 2016Beat AML
NCT00648739Phase 1/Phase 2 (Phase 2)Jun 1, 2008Alexion, Duke University, Emory University, HOANNJ-Carol G. Simon Cancer Center, University of Arizona, University of Michigan
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AlexionFor profit2222008
Beat AMLAcademic/Hospital1112016
Duke UniversityAcademic/Hospital1012008
Emory UniversityAcademic/Hospital1012008
HOANNJ-Carol G. Simon Cancer CenterAcademic/Hospital1012008
IQVIAFor profit1012016
University of ArizonaAcademic/Hospital1012008
University of MichiganAcademic/Hospital1012008
8 organizations
Page 1 / 1